Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Social services

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    83 result(s) found for: Social services. Displaying page 4 of 5.
    « Previous 1  2  3  4  5  Next»
    EudraCT Number: 2018-002869-18 Sponsor Protocol Number: Start Date*: 2019-09-04
    Sponsor Name:Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust
    Full Title: A randomised, double-blind, placebo controlled trial of pramipexole in addition to mood stabilisers for patients with treatment resistant bipolar depression.
    Medical condition: Bipolar disorder (BD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10012386 Depression mental LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2015-002530-50 Sponsor Protocol Number: EspeRare_RIM_001 Start Date*: 2015-11-04
    Sponsor Name:EspeRare
    Full Title: A phase Ib, open label study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending oral doses of Rimeporide in patients with Duchenne Muscular Dystrophy.
    Medical condition: Duchenne Muscular Dystrophy (DMD)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: ES (Completed) GB (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000350-26 Sponsor Protocol Number: CL09-ORY-2001 Start Date*: 2021-07-06
    Sponsor Name:Oryzon Genomics, S.A.
    Full Title: A double blind, randomized, placebo-controlled, adaptive 24-week Phase IIb trial to evaluate the efficacy of vafidemstat in negative symptoms and cognitive impairment associated with schizophrenia....
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-005726-15 Sponsor Protocol Number: 217102 Start Date*: 2022-05-17
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A 52-week, randomized, double-blind, double-dummy, parallel-group, multi-centre, non-inferiority study to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with...
    Medical condition: Relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) receiving standard of care (SoC) therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10078117 Eosinophilic granulomatosis with polyangiitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Trial now transitioned) IT (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) HU (Trial now transitioned) PT (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-004932-19 Sponsor Protocol Number: OMB110911 Start Date*: 2009-01-27
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A phase III, open label, randomized, multicenter trial of Ofatumumab added to Chlorambucil vs. Chlorambucil Monotherapy in previously untreated patients with Chronic Lymphocytic Leukemia
    Medical condition: Chronic Lymphocytic Leukaemia
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008976 Chronic lymphocytic leukemia LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    17.0 10005329 - Blood and lymphatic system disorders 10024324 Leukaemias HLGT
    17.0 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    17.0 10005329 - Blood and lymphatic system disorders 10024295 Leukaemias chronic lymphocytic HLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008959 Chronic lymphocytic leukaemia (in remission) PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) IE (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) SE (Completed) BE (Prematurely Ended) CZ (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended) GR (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-022838-85 Sponsor Protocol Number: MEK114267 Start Date*: 2010-12-21
    Sponsor Name:Novartis Pharma Services AG
    Full Title: MEK114267, A Phase III randomized, open-label study comparing GSK1120212 to chemotherapy in subjects with advanced or metastatic BRAF V600E/K mutation-positive melanoma
    Medical condition: Advanced or metastatic BRAF V600E/K mutation-positive melanoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) BE (Completed) CZ (Completed) GR (Completed) NO (Completed) GB (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-017950-11 Sponsor Protocol Number: ING113086 Start Date*: 2010-11-10
    Sponsor Name:ViiV Healthcare S.L
    Full Title: Estudio fase III, aleatorizado, doble ciego, para evaluar la eficacia y la seguridad de 50 mg de GSK1349572 una vez al día, frente a 400mg de raltegravir dos veces al día, ambos administrados con u...
    Medical condition: Pacientes adultos infectados por el VIH-1 que no han recibido tratamiento antirretroviral previo
    Disease: Version SOC Term Classification Code Term Level
    12.1 10008922 Chronic infection with HIV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) FR (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022638-96 Sponsor Protocol Number: CAFQ056B2214 Start Date*: 2011-06-15
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of AFQ056 in adolescent patients with Fragile X Syndrome
    Medical condition: Fragile X Syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10017324 Fragile X syndrome PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) FR (Completed) DK (Completed) DE (Completed) ES (Completed) Outside EU/EEA IT (Completed) BE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-001897-13 Sponsor Protocol Number: ITM-LET-01 Start Date*: 2017-08-22
    Sponsor Name:ITM Solucin GmbH
    Full Title: A prospective, randomised, Controlled, Open-label, Multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to tar...
    Medical condition: Patients with inoperable, progressive, somatostatin receptor-positive(SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077559 Gastroenteropancreatic neuroendocrine tumour disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) CZ (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-001220-30 Sponsor Protocol Number: EGF117165 Start Date*: 2014-07-25
    Sponsor Name:GlaxoSmithKline, S.A.
    Full Title: An Open-Label, Phase II, Study to Evaluate Biomarkers Associated with Response to Subsequent Therapies in Subjects with HER2-Positive Metastatic Breast Cancer Receiving Treatment with Trastuzumab i...
    Medical condition: HER2 positive Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Prematurely Ended) IT (Completed) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-004436-34 Sponsor Protocol Number: CSOM230Y2201 Start Date*: 2017-02-06
    Sponsor Name:Novartis Pharma AG
    Full Title: A Multicenter, Placebo-Controlled, Single Dose Study in Acute Episodic and Chronic Cluster Headache to Evaluate the Safety and Efficacy of SOM230 subcutaneous (s.c.)
    Medical condition: Cluster headache
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10059133 Cluster headache PT
    20.0 10029205 - Nervous system disorders 10009698 Cluster headaches LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001711-31 Sponsor Protocol Number: D1050238 Start Date*: 2012-02-29
    Sponsor Name:Sunovion Pharmaceuticals Inc.
    Full Title: A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance treatment of subjects with schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-005696-14 Sponsor Protocol Number: 6451 Start Date*: 2013-09-19
    Sponsor Name:Newcastle upon Tyne Hospitals NHS Foundation Trust
    Full Title: A phase 3 randomised non-inferiority trial to evaluate the use of imatinib, nilotinib and ponatinib in patients with newly-diagnosed chronic phase chronic myeloid leukaemia
    Medical condition: Chronic phase Chronic Myeloid Leukaemia
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004864 10052065 Chronic phase chronic myeloid leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000201-24 Sponsor Protocol Number: O3Cardio Start Date*: 2018-08-01
    Sponsor Name:Bernardino Clavo - Hospital Dr. Negrín
    Full Title: Effectiveness and cost-effectiveness of Ozone therapy in patients with ischemic heart disease refractory to medical and surgical treatment: Randomized, triple-blind clinical trial.
    Medical condition: Ischemic heart disease refractory to medical and surgical treatment.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10019279 Heart failure LLT
    20.0 100000004849 10055224 Cardiac ischemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-014858-15 Sponsor Protocol Number: TRC112765 Start Date*: 2010-10-27
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR),...
    Medical condition: chemotherapy induced thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10043554 Thrombocytopenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) IE (Completed) GR (Completed) FI (Completed) HU (Completed) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-020983-39 Sponsor Protocol Number: ING114467 Start Date*: 2010-12-30
    Sponsor Name:ViiV Healthcare UK Limited
    Full Title: A Phase 3, randomized, double-blind study of the safety and efficacy of GSK1349572 plus abacavir/lamivudine fixed-dose combination therapy administered once daily compared to Atripla over 96 weeks ...
    Medical condition: HIV-1 infected antiretroviral therapy naive adult subjects.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10008922 Chronic infection with HIV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) ES (Completed) GB (Completed) HU (Completed) DK (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-001637-27 Sponsor Protocol Number: LQD Start Date*: 2016-09-20
    Sponsor Name:South London and Maudsley NHS Foundation Trust [...]
    1. South London and Maudsley NHS Foundation Trust
    2. King's College London
    Full Title: A randomised pragmatic trial comparing the clinical and cost effectiveness of lithium and quetiapine augmentation in treatment resistant depression.
    Medical condition: Treatment resistant major depressive disorder (single episode or recurrent). Treatment resistant depression, defined as failure to respond to two or more adequate doses of antidepressant in the cur...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10067373 Depression perimenopausal LLT
    21.1 10037175 - Psychiatric disorders 10066555 Chronic depression LLT
    21.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    20.0 10037175 - Psychiatric disorders 10012391 Depression postpartum (excl psychosis) LLT
    20.0 10022117 - Injury, poisoning and procedural complications 10012390 Depression postoperative PT
    20.0 10037175 - Psychiatric disorders 10012386 Depression mental LLT
    21.1 10037175 - Psychiatric disorders 10066530 Acute depression LLT
    20.0 10037175 - Psychiatric disorders 10012389 Depression postmenopausal LLT
    20.0 10037175 - Psychiatric disorders 10012387 Depression NOS LLT
    20.0 10037175 - Psychiatric disorders 10012378 Depression PT
    21.1 10037175 - Psychiatric disorders 10045543 Unipolar depression LLT
    21.1 10037175 - Psychiatric disorders 10037998 Reactive depression LLT
    21.1 10037175 - Psychiatric disorders 10042457 Suicidal depression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2022-001627-32 Sponsor Protocol Number: CVAY736Q12301 Start Date*: 2023-03-15
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase 3 randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to eltrombopag in patients with primary immune thrombocytopenia (ITP) who had an insufficient response or r...
    Medical condition: immune thrombocytopenia (ITP)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10005329 - Blood and lymphatic system disorders 10083842 Immune thrombocytopenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) CZ (Trial now transitioned) HU (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) NO (Trial now transitioned) ES (Ongoing) AT (Trial now transitioned) BE (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-010939-40 Sponsor Protocol Number: PLEASE Start Date*: 2010-04-29
    Sponsor Name:UMCN St Radboud
    Full Title: PLEASE Persistent Lyme Empiric Antibiotic Study Europe. A prospective, randomised study comparing two prolonged oral antibiotic strategies after initial intravenous ceftriaxone therapy for patients...
    Medical condition: Persistent Lyme disease Persistent borreliosis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10025169 Lyme disease LLT
    12.0 10025170 Lyme's disease LLT
    12.0 10067559 Lyme borreliosis LLT
    12.0 10006036 Borrelia burgdorferi infection LLT
    12.0 10061591 Borrelia infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2011-000114-19 Sponsor Protocol Number: TRC114968 Start Date*: 2011-11-29
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A Three-part Study of Eltrombopag in Thrombocytopenic Subjects with Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: open-label, Part 2: randomized, double-blind, Part 3: extension). A...
    Medical condition: Thrombocytopenic Subjects with advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10060356 Acute myeloid leukaemia without mention of remission LLT
    17.0 100000004864 10028534 Myelodysplastic syndrome NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) CZ (Completed) GR (Completed) ES (Completed) IE (Completed) PL (Completed) HU (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 07:13:45 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA